Apimeds Pharmaceuticals US Overview
Latest ROE for Apimeds Pharmaceuticals US: -54.65% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-54.65%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for APUS is -54.65%. That is below the sector sector average of -5.68%. Investors often review this figure alongside Apimeds Pharmaceuticals US's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, APUS currently prints -54.65% for ROE, while the sector average sits near -5.68%. That is roughly 861.5% below the sector mean. Large gaps often invite a closer look at Apimeds Pharmaceuticals US's growth, margins, and balance sheet.
Return on Equity shows how effectively Apimeds Pharmaceuticals US converts resources into returns. At -54.65%, APUS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting APUS's ROE (-54.65%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
